Evidence map›Paper›PMID 39679639›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2025

Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis.

Antonio Molinaro, Lise Katrine Engesæter, Carl Jorns, Arno Nordin, Allan Rasmussen, Pål-Dag Line, Virge Pall, Bo-Göran Ericzon, William Bennet, Johannes R Hov and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Antonio MolinaroDepartment of Molecular and Clinical Medicine, Wallenberg Laboratory, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-3432-2238
Lise Katrine EngesæterNorwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.
Carl JornsDivision of Transplantation Surgery, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-7727-8113
Arno NordinDepartment of Transplantation and Liver Surgery, University Hospital, Helsinki, Finland.
Allan RasmussenDepartment of Surgical Gastroenterology and Liver Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pål-Dag LineInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Virge PallTransplantation Centre, Tartu University Hospital, Tartu, Estonia.
Bo-Göran EriczonDivision of Transplantation Surgery, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
William BennetTransplant Institute, Sahlgrenska University Hospital, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Johannes R HovNorwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-5900-8096
Espen MelumNorwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.ORCID 0000-0001-6903-6878

Funding

ERC grant (no. 802544)Regional Healthy Authorities South-Eastern Norway (no. 2017022)Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-934173)
6 · The paper itself

Abstract

BACKGROUND AND

aimsPrimary sclerosing cholangitis (PSC) is among the most common indications for liver transplantation in the Nordic countries and with an increasing trend in Europe and North America. Due to post-transplant complications and high prevalence of disease recurrence this group is at risk of requiring retransplantation (re-LTX). Results from re-LTX for PSC are not extensively studied and there is a lack of knowledge regarding prognosis after re-LTX in this population.

methodsGraft and patient survival after re-LTX for patients with PSC and a comparable comparison group from the Nordic liver transplant registry were analysed. One-hundred and eighty-five patients with PSC and 208 patients in the comparison group were included.

resultsThe graft and patient survival were better for patients with PSC compared to the comparison group (p < 0.001). Re-LTX for recurrence of PSC (rPSC) compared to other aetiologies had similar and better outcomes for graft and patient survival (p = 0.093 and p = 0.023, respectively). Moreover, re-LTX for rPSC compared to the comparison group had a lower 30-day and 5-year mortality (p < 0.001 and p = 0.041, respectively).

conclusionOutcomes after retransplantation for PSC were similar or better compared to the comparison group. Retransplantation represents a treatment option with the potential for excellent outcomes in patients with PSC and should be considered in transplanted PSC patients with graft failure.

Indexed as

Cholangitis, SclerosingGraft SurvivalLiver TransplantationRecurrenceReoperationAdultFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesScandinavian and Nordic CountriesTreatment Outcomeliver transplantationprimary sclerosing cholangitisretransplantation

Identifiers

PMID39679639
PMCPMC11648066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.